SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Kinnate Biopharma Inc. (KNTE) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+1032.1%).
- Analyst consensus target $30.00 (+1032.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KNTE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.42
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$30.00 (+1032.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.71 |
$0.00 |
$-7.63M |
- |
| 2019 |
$-0.28 |
$0.00 |
$-11.93M |
- |
| 2020 |
$-0.81 |
$0.00 |
$-35.43M |
- |
| 2021 |
$-2.05 |
$0.00 |
$-89.42M |
- |
| 2022 |
$-2.59 |
$0.00 |
$-114.02M |
- |
| 2023 |
$-2.42 |
$0.00 |
$-112.65M |
- |
